As a testament to both the rigor and importance of Dr. Brinton's science, her breakthrough research has been continuously funded by rigorously peer-reviewed grants from the National Institutes of Health and private foundations including the Alzheimer’s Drug Discovery Foundation, and the Alzheimer’s Association.  Her current funding sources include:

 

  • Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment

National Institute on Aging (NIA)

R01AG059093

Principal Investigator

 

  • Sex Differences in the Molecular Determinants of Alzheimer’s Disease Risk: Prodromal Endophenotype

National Institute on Aging (NIA)

R01AG057931

Principal Investigator

 

  • Advancing Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s

Alzheimer’s Association

Principal Investigator

 

  • Convergence of Maternal History of AD Mitochondrial Haplotype, ApoE Genotype and Ethnic Heritage: Relationship to Alzheimer’s Disease

Arizona Alzheimer’s Association

Principal Investigator

 

  • Perimenopause in Brain Aging and Alzheimer’s Disease

National Institute on Aging (NIA)

P01-AG026572

Principal Investigator

 

  • Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I

National Institute on Aging (NIA)

UF1-AG046148     

Principal Investigator

 

  • Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicology

National Institute on Aging (NIA)

U01-AG047222

Principal Investigator

 

  • Aging and Estrogenic Control of the Bioenergetic System in Brain      

National Institute on Aging (NIA)

R37AG053589 MERIT Award                                                                                 

Principal Investigator

 

  • ApoE4: Accelerator of Bioenergetic Aging in Female Brain and Risk of Alzheimer’s Disease Sex and Gender in Alzheimer’s (SAGA)

Alzheimer’s Association                                

Principal Investigator

 

  • Manufacturing of Allopragnanolone for Phase 2 Clinical Trial

Alzheimer’s Drug Discovery Foundation                                                                  

Principal Investigator

                                                                       

  • Allopregnanolone Novel Patentable Formulations to Advance Commercialization     

Alzheimer’s Drug Discovery Foundation Goodes Award                                        

Principal Investigator

 

  • ApoE4: Accelerator of Bioenergetic Aging in Female Brain and Risk of Alzheimer’s Disease

Arizona Alzheimer’s Consortium

Principal Investigator

 

Changing the way we do brain science.